Sylvia Herter

11PUBLICATIONS
103CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Oncology and carcinogenesis not elsewhere classifiedMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 16, 2026
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

|Jul 16, 2026
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

|Jun 12, 2026
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

|Feb 26, 2026
Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL.

Paul Marcoux, Fabien Gava, Marie Tosolini

|Jan 22, 2026
Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Stephan Schmeing, Sina Nassiri, Gabrielle Leclercq-Cohen

|Aug 01, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Johannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt

Pageof 2

Frequent Collaborators

7 joint publications

Christian Klein

6 joint publications

Marina Bacac

4 joint publications

Johannes Sam

4 joint publications

Tamara Hüsser